| First Author | Amano Y | Year | 2018 |
| Journal | Biochem Biophys Res Commun | Volume | 497 |
| Issue | 1 | Pages | 207-213 |
| PubMed ID | 29428719 | Mgi Jnum | J:272470 |
| Mgi Id | MGI:6280395 | Doi | 10.1016/j.bbrc.2018.02.055 |
| Citation | Amano Y, et al. (2018) Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun 497(1):207-213 |
| abstractText | This study aimed to evaluate the effects of combination therapy with a dipeptidyl peptidase-4 inhibitor, alogliptin, and a peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, in a preclinical model of nonalcoholic steatohepatitis using low-density lipoprotein receptor-knockout mice fed a modified choline-deficient l-amino acid-defined diet. Monotherapy with either alogliptin (10-200mg/kg) or pioglitazone (6-20mg/kg) significantly decreased hepatic triglyceride content and fibrosis. The concomitant treatment of alogliptin (30mg/kg), pioglitazone (20mg/kg) also decreased hepatic triglyceride and hepatic collagen-I mRNA at greater extent compared to monotherapy. Hepatic expression of CD11b mRNA and monocyte chemoattractant protein-1 were also reduced by the concomitant treatment. These results suggest that via an anti-inflammatory potential in addition to anti-metabolic effects, the combination therapy of alogliptin and pioglitazone may provide therapeutic benefits to type 2 diabetes patients with nonalcoholic steatohepatitis, which will be proven in controlled clinical trials. |
